Palivizumab Antibody | AbD23967_hIgG1

//www.bio-rad-antibodies.com/palivizumab-antibody-abd23967-higg1-hca262.html
Palivizumab Antibody | AbD23967_hIgG1 gallery image 1

Human anti palivizumab specificity ELISA
A microtiter plate was coated over night with various antigens at a concentration of 5 μg/ml. After washing and blocking with PBST+5% BSA, detection was performed using HRP conjugated human anti palivizumab (clone AbD23967_hIgG1) at a concentration of 2 μg/ml in HISPEC diluent (BUF049A) and QuantaBlu™ fluorogenic peroxidase substrate

Enlarge
Palivizumab Antibody | AbD23967_hIgG1 gallery image 2

Human anti palivizumab specificity titration ELISA
A microtiter plate was coated over night with palivizumab, human IgG1/kappa or human IgG1/lambda at a concentration of 5 μg/ml. After washing and blocking with PBST+5% BSA, detection was performed using increasing concentrations of HRP conjugated human anti palivizumab (clone AbD23967_hIgG1) in HISPEC diluent (BUF049A) and QuantaBlu™ fluorogenic peroxidase substrate. Data for binding to palivizumab is presented as the mean of three measurements

Enlarge
Palivizumab Antibody | AbD23967_hIgG1 gallery image 3

Palivizumab bridging ELISA for pharmacokinetic (PK) assay development
A microtiter plate was coated over night with human anti palivizumab (clone AbD23967) at a concentration of 1 μg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of palivizumab. Detection was performed using HRP-conjugated human anti palivizumab (clone AbD23967_hIgG1) at a concentration of 2 μg/ml in HISPEC assay diluent (BUF049A) and QuantaBlu™ fluorogenic peroxidase substrate. Data is presented as the mean of three measurements

Enlarge
Palivizumab Antibody | AbD23967_hIgG1 gallery image 4

Palivizumab bridging ELISA for pharmacokinetic (PK) assay development
A microtiter plate was coated over night with human anti palivizumab (clone AbD23967_hIgG1) at a concentration of 0.5 μg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of palivizumab. Detection was performed using HRP-conjugated human anti palivizumab (clone AbD23967_hIgG1) at a concentration of 2 μg/ml in HISPEC assay diluent (BUF049A) and QuantaBlu™ fluorogenic peroxidase substrate. Data is presented as the mean of three measurements

Enlarge
Palivizumab Antibody | AbD23967_hIgG1 gallery image 5

Human anti palivizumab bridging ELISA for ADA assay development
A microtiter plate was coated over night with palivizumab at concentrations between 0.5 and 1.5 μg/ml. After washing and blocking with PBST+5% BSA, PBST with 10% human serum was added spiked with increasing concentrations of human anti palivizumab (clone AbD23967_hIgG1). Detection was performed using HRP conjugated palivizumab at a concentration of 2 μg/ml in HISPEC assay diluent (BUF049A) and QuantaBlu™ fluorogenic peroxidase substrate. Data is presented as the mean of three measurements. HRP-conjugation of the antibody used in this assay was performed using a LYNX Rapid HRP Antibody Conjugation Kit®

Enlarge
  • Palivizumab Antibody | AbD23967_hIgG1 thumbnail image 1
  • Palivizumab Antibody | AbD23967_hIgG1 thumbnail image 2
  • Palivizumab Antibody | AbD23967_hIgG1 thumbnail image 3
  • Palivizumab Antibody | AbD23967_hIgG1 thumbnail image 4
  • Palivizumab Antibody | AbD23967_hIgG1 thumbnail image 5
  • Human anti Palivizumab
  • Human anti Palivizumab:HRP
(Rated 0.0 out of 5 based on 0 customer reviews)
    Anti-palivizumab antibody is a recombinant, neutralizing, anti-idiotypic antibody in fully human IgG1 format for bioanalytical assays to measure palivizumab and biosimilars. It can be used as the detection antibody in a PK bridging ELISA and as a reference standard in an ADA bridging ELISA.
    • Product Type
      Monoclonal Antibody
    • Clone
      AbD23967_hIgG1
    • Isotype
      IgG1
    2 Formats Available
      Product CodeApplicationsDatasheetMSDSPack SizeList PriceQuantity
      HCA262Edatasheet pdfdatasheet pdf0.1 mg
      HCA262
      HCA262PEdatasheet pdfdatasheet pdf0.1 mg
      HCA262P
      Summary
      Secondary Antibodies
      Negative Isotype Controls
      Useful Reagents
      Positive Controls
      Histology Controls
      More Images
      References
      Reviews
      -
      • Human anti Palivizumab, clone AbD23967_hIgG1, is a paratope specific, high affinity, anti-idiotypic antibody that specifically recognizes the monoclonal antibody drug palivizumab and inhibits it binding to its target. The antibody can be used to measure the levels of palivizumab and biosimilar products in bioanalytical assays.

        Clone AbD23967_hIgG1 is a fully human recombinant monoclonal antibody with IgG1 isotype and is suitable as a reference standard in an anti-drug antibody (ADA) assay. Additionally the antibody can be used to develop a pharmacokinetic (PK) bridging assay to measure free drug. This antibody is recommended as the detection antibody and is available unlabeled or directly conjugated to HRP. Use in a pair with capture antibody clone AbD23967 (HCA261) in monovalent Fab format.

        Palivizumab (Synagis®) is a humanized mouse monoclonal antibody (IgG1/kappa) specific to an epitope of the F protein of respiratory syncytial virus (RSV). It binds the antigenic site A, a highly conserved region on the RSV F protein between amino acids 258 and 275. RSV is known to cause infections of the lower respiratory tract in a clear seasonal pattern during the winter months. Administration of the drug is recommended for premature infants (under 35 weeks gestation), infants with certain congenital heart defects (CHD) or bronchopulmonary dysplasia (BPD) throughout the duration of the RSV season. It is approved by the FDA and EMA as a treatment for respiratory tract infection caused by RSV.

        View a summary of all anti-palivizumab antibodies
      • Intended Use
      • Product Form
        Human IgG1 antibody selected from the HuCAL® phage display library and expressed in a human cell line.
        Human IgG1 antibody selected from the HuCAL® phage display library and expressed in a human cell line. Conjugated to horseradish peroxidase (HRP) - liquid.
      • Reconstitution
      • Preparation
        Purified IgG prepared by affinity chromatography on Protein A
        Purified IgG prepared by affinity chromatography on Protein A
      • Preservative Stabilisers
        0.01% Thiomersal
        0.01% Thiomersal
      • Immunogen
        Palivizumab
      • Purity
      • Affinity
        The monovalent intrinsic affinity of this antibody was measured as KD = 1.5 nM by real time, label free molecular interaction analysis on immobilized palivizumab.
      • Approx. Protein Concentrations
        Antibody concentration 0.5 mg/ml
        IgG concentration 0.1 mg/ml
      • Reagents In The Kit
      • Preparing The Antibody
      • Test Principle
      • Buffer Solution
        Phosphate buffered saline
        Phosphate buffered saline
      • Storage
        Store at +4oC or at -20oC if preferred.
        Storage in frost-free freezers is not recommended.
        This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
        Store at -70oC.
        Storage in frost-free freezers is not recommended.
        This product should be stored undiluted.
      • Shelf Life
        12 months from date of despatch
        12 months from date of despatch.
      • Acknowledgements
        Sold under license of U.S. Patents 6,300,064, 6,696,248, 6,708,484, 6,753,136, European Patent 0,859,841 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany, a wholly owned subsidiary of Bio-Rad Laboratories Inc.

        Synagis® is a registered trademark of the AstraZeneca group of companies.
        Sold under license of U.S. Patents 6,300,064, 6,696,248, 6,708,484, 6,753,136, European patent 0,859,841 and corresponding patents. This antibody was developed by Bio-Rad, a wholly owned subsidiary of Bio-Rad Laboratories Inc., Zeppelinstr. 4, 82178 Puchheim, Germany. Synagis® is a registered trademark of the AstraZeneca group of companies.
      • Licensed Use
        For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
      • Regulatory
        For research purposes only
      • This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.

      • Application NameYesNoMin DilutionMax Dilution
        ELISA
      • Application NameYesNoMin DilutionMax Dilution
        ELISA

      • Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
      • Technical Advice
        Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
      • Technical Advice
        Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
      • Recommended Protocol
      • Recommended Protocol
      • ELISA
        This product may be used in direct or indirect ELISA and in an ELISA bridging assay as a capture or detection antibody together with the same antibody or HCA261 as the paired reagent. It is also suitable as a fully human control or calibrator antibody in an ADA bridging ELISA.
        Protocol: PK bridging ELISA to measure free drug
      • ELISA
        This product may be used as a detection reagent in a sandwich ELISA together with HCA261 as the capture reagent.
        Protocol: PK bridging ELISA to measure free drug
      • Immunohistology
      • Immunohistology
      • Histology Positive Control Tissue
      • Histology Positive Control Tissue
      • Immunofluorescence
      • Immunofluorescence
      • Western Blotting
      • Western Blotting
      • Instructions For Use
      • Instructions For Use

      Additional Palivizumab Antibody Formats

      Formats Clone Applications Sizes available
      Palivizumab Antibody : Purified AbD23967_hIgG1 E 0.1 mg
      Palivizumab Antibody : HRP AbD23967_hIgG1 E 0.1 mg
      • Copyright © 2016 Bio-Rad Antibodies (formerly AbD Serotec)

      Recommended Secondary Antibody

        Recommended Negative Isotype Control

          Useful Reagents

            DescriptionProduct CodePack SizeApplicationsList PriceQuantity
            LYNX Rapid HRP Antibody Conjugation KitLNK002P3 Conjugations For 400µg AntibodyCJ
            LNK002P
            Human anti PalivizumabHCA2610.1 mgE
            HCA261
            Hispec Assay DiluentBUF049A50 mlIY
            BUF049A
            DescriptionProduct CodePack SizeApplicationsList PriceQuantity
            Human anti PalivizumabHCA2610.1 mgE
            HCA261
            Human anti PalivizumabHCA2620.1 mgE
            HCA262
            Hispec Assay DiluentBUF049A50 mlIY
            BUF049A

            Recommended Positive Controls

              Histology Controls

                Write your review

                You may also be interested in...

                You May Also Be Interested In...